Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Inflammatory Bowel Diseases

Free Subscription 24.09.2018 1 BMC Gastroenterol 4 Clin Gastroenterol Hepatol 1 Dig Dis Sci 1 Dis Colon Rectum 4 Eur J Gastroenterol Hepatol 2 Gastroenterology 3 Gut 3 J Crohns Colitis 2 Lancet 1 Mediators Inflamm 3 Scand J Gastroenterol

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

BMC Gastroenterol

1. SCHNEIDER AM, Weghuber D, Hetzer B, Entenmann A, et al
   Vedolizumab use after failure of TNF-alpha antagonists in children and adolescents with inflammatory bowel disease.
   BMC Gastroenterol. 2018;18:140.
   PubMed     Text format     Abstract available
   
   

   
   Clin Gastroenterol Hepatol

2. RAFFALS LE, Nguyen GC, Rubin DT, Nguyen GC, et al
   Switching Between Biologics and Biosimilars in Inflammatory Bowel Disease.
   Clin Gastroenterol Hepatol. 2018 Sep 6. pii: S1542-3565(18)30943.
   PubMed     Text format    
   
   
3. PELLET G, Stefanescu C, Carbonnel F, Peyrin-Biroulet L, et al
   Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination with Vedolizumab in Patients With Refractory Ulcerative Colitis.
   Clin Gastroenterol Hepatol. 2018 Sep 10. pii: S1542-3565(18)30966.
   PubMed     Text format     Abstract available
   
   
4. MORILLA I, Uzzan M, Laharie D, Cazals-Hatem D, et al
   Colonic microRNA Profiles, Identified by a Deep-learning Algorithm, That Predict Responses of Patients With Acute Severe Ulcerative Colitis to Therapy.
   Clin Gastroenterol Hepatol. 2018 Sep 14. pii: S1542-3565(18)30947.
   PubMed     Text format     Abstract available
   
   
5. SOMINENI HK, Kugathasan S
   The microbiome in inflammatory bowel disease: from prevailing clinical evidence to future possibilities.
   Clin Gastroenterol Hepatol. 2018 Sep 6. pii: S1542-3565(18)30957.
   PubMed     Text format    
   
   

   
   Dig Dis Sci

6. KIM ES, Kim SK, Jang BI, Kim KO, et al
   Disease Activity Patterns Recorded Using a Mobile Monitoring System Are Associated with Clinical Outcomes of Patients with Crohn's Disease.
   Dig Dis Sci. 2018;63:2220-2230.
   PubMed     Text format     Abstract available
   
   

   
   Dis Colon Rectum

7. BENLICE C, Holubar SD, Gorgun E, Stocchi L, et al
   Extended Venous Thromboembolism Prophylaxis After Elective Surgery for IBD Patients: Nomogram-Based Risk Assessment and Prediction from Nationwide Cohort.
   Dis Colon Rectum. 2018;61:1170-1179.
   PubMed     Text format     Abstract available
   
   

   
   Eur J Gastroenterol Hepatol

8. PERNAT DROBEZ C, Repnik K, Gorenjak M, Ferkolj I, et al
   DNA polymorphisms predict time to progression from uncomplicated to complicated Crohn's disease.
   Eur J Gastroenterol Hepatol. 2018;30:447-455.
   PubMed     Text format     Abstract available
   
   
9. MERAL M, Bengi G, Kayahan H, Akarsu M, et al
   Is ileocecal valve intubation essential for routine colonoscopic examination?
   Eur J Gastroenterol Hepatol. 2018;30:432-437.
   PubMed     Text format     Abstract available
   
   
10. BLACKETT JW, Shamsunder M, Reilly NR, Green PHR, et al
    Characteristics and comorbidities of inpatients without celiac disease on a gluten-free diet.
    Eur J Gastroenterol Hepatol. 2018 Jan 8. doi: 10.1097/MEG.0000000000001071.
    PubMed     Text format     Abstract available
    
    
11. HOLKO P, Kawalec P, Stawowczyk E
    Prevalence and drug treatment practices of inflammatory bowel diseases in Poland in the years 2012-2014: an analysis of nationwide databases.
    Eur J Gastroenterol Hepatol. 2018;30:456-464.
    PubMed     Text format     Abstract available
    
    

    
    Gastroenterology

12. SORRENTINO DR
    Therapeutic Targets in Inflammatory Bowel Disease: Are We Getting the Point Across?
    Gastroenterology. 2018 Sep 14. pii: S0016-5085(18)34773.
    PubMed     Text format    
    
    
13. KELLY CP, Wilcox MH, Glerup H, Aboo N, et al
    Bezlotoxumab for Clostridium difficile Infection Complicating Inflammatory Bowel Disease.
    Gastroenterology. 2018 Sep 15. pii: S0016-5085(18)34757.
    PubMed     Text format    
    
    

    
    Gut

14. SANDBORN WJ, Lee SD, Tarabar D, Louis E, et al
    Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study.
    Gut. 2018;67:1824-1835.
    PubMed     Text format     Abstract available
    
    
15. GERNER RR, Klepsch V, Macheiner S, Arnhard K, et al
    NAD metabolism fuels human and mouse intestinal inflammation.
    Gut. 2018;67:1813-1823.
    PubMed     Text format     Abstract available
    
    
16. LEVINE A, Sigall Boneh R, Wine E
    Evolving role of diet in the pathogenesis and treatment of inflammatory bowel diseases.
    Gut. 2018;67:1726-1738.
    PubMed     Text format     Abstract available
    
    

    
    J Crohns Colitis

17. VAN HOEVE K, Dreesen E, Hoffman I, Van Assche G, et al
    Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease.
    J Crohns Colitis. 2018 Sep 19. pii: 5103494. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
18. PEREIRA MS, Maia L, Azevedo LF, Campos S, et al
    A (glyco)biomarker that predicts failure to standard therapy in Ulcerative Colitis patients.
    J Crohns Colitis. 2018 Sep 20. pii: 5104327. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
19. KIERNAN MG, Coffey JC, McDermott K, Cotter PD, et al
    The human mesenteric lymph node microbiome differentiates between Crohn's disease and ulcerative colitis.
    J Crohns Colitis. 2018 Sep 15. pii: 5098279. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    Lancet

20. KUGATHASAN S, Denson LA, Hyams JS
    Exclusive and partial enteral nutrition for Crohn's disease - Authors' reply.
    Lancet. 2017;390:1486-1487.
    PubMed     Text format    
    
    
21. SENUSSI NH
    Exclusive and partial enteral nutrition for Crohn's disease.
    Lancet. 2017;390:1486.
    PubMed     Text format    
    
    

    
    Mediators Inflamm

22. CHARPENTIER C, Chan R, Salameh E, Mbodji K, et al
    Dietary n-3 PUFA May Attenuate Experimental Colitis.
    Mediators Inflamm. 2018;2018:8430614.
    PubMed     Text format     Abstract available
    
    

    
    Scand J Gastroenterol

23. LINDSTROM L, Jorgensen KK, Boberg KM, Castedal M, et al
    Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: a Nordic Multicentre Study.
    Scand J Gastroenterol. 2018 Jan 4:1-8. doi: 10.1080/00365521.2017.1421705.
    PubMed     Text format     Abstract available
    
    
24. AALTONEN G, Ristimaki A, Keranen I, Carpelan-Holmstrom M, et al
    Does a histologically inflamed resection margin increase postoperative complications in patients with Crohn's disease?
    Scand J Gastroenterol. 2018;53:279-283.
    PubMed     Text format     Abstract available
    
    
25. STEIN J, Walper A, Klemm W, Farrag K, et al
    Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice.
    Scand J Gastroenterol. 2018 Sep 17:1-7. doi: 10.1080/00365521.2018.1498914.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: